The Spanish pharmaceutical industry is facing potential supply chain disruptions due to geopolitical tensions, particularly concerning dependency on active pharmaceutical ingredients from other countries.
The article discusses the vulnerabilities in the pharmaceutical supply chain, particularly highlighting the concerns raised by the director of the Spanish Medicines Agency regarding the reliance on active pharmaceutical ingredients (APIs) sourced from countries like India and China. It notes that while Europe perceives itself as having substantial autonomy in drug production, the realities of logistics and supply come into play, especially given the rising costs associated with air transport, which have surged between 30% and 100%.
Additionally, the text warns about the repercussions of external conflicts, specifically citing the ongoing war in Iran and its potential to disrupt supplies to the pharmaceutical industry. The Spanish laboratory associations are keen to monitor these developments as they project that by April, clearer effects on trade flows with the Middle East and Asia could be assessed. This uncertainty could affect the availability of essential drugs and raise alarms over the national capacity to deal with pharmaceuticals supply challenges.
Furthermore, the article underscores the necessity for a strategic reassessment within the European pharmaceutical landscape to enhance resilience against such supply chain risks. The implications of this situation extend beyond economic aspects, affecting public health and the timely availability of vital medications, a growing concern in light of recent global events that have tested healthcare infrastructures worldwide.
